PHASE I TRIAL OF TG02 PLUS DOSE-DENSE OR METRONOMIC TEMOZOLOMIDE FOR RECURRENT HIGH-GRADE ASTROCYTOMA IN ADULTS

被引：0

作者：

Wu, Jing ^{[1
]}

Bryla, Christine ^{[1
]}

Su, Yu-Ting ^{[1
]}

Grajkowska, Ewa ^{[1
]}

McCoy, Ann ^{[2
]}

Boris, Lisa ^{[1
]}

Antony, Ramya ^{[1
]}

Garren, Nancy ^{[2
]}

Siegel, Christine ^{[1
]}

Cordova, Christine ^{[1
]}

Aboud, Orwa ^{[1
]}

Vera, Elizabeth ^{[1
]}

Lawhon, Tracy ^{[3
]}

Penas-Prado, Marta ^{[1
]}

Theeler, Brett ^{[1
]}

Mendoza, Tito ^{[4
]}

Armstrong, Terri ^{[1
]}

Yuan, Ying ^{[4
]}

Gilbert, Mark ^{[1
]}

机构：

[1] NCI, Neurooncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA

[2] NCI, Bethesda, MD 20892 USA

[3] Adastra Pharmaceut Inc, San Diego, CA USA

[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

NEURO-ONCOLOGY | 2019年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ACTR-62

引用

页码：27 / 28

页数：2

共 50 条

[21] Temozolomide dose-dense regimen in high grade gliomas: dose-finding/phase II study
Napoleoni, L.
Bruera, G.
Adinolfi, M. I.
Catalucci, A.
Bonfili, P.
Di Staso, M.
Ricci, A.
Di Cesare, E.
Galzio, R. J.
Ricevuto, E.
ANNALS OF ONCOLOGY, 2015, 26 : 138 - 138
[22] PHASE I TRIAL OF DNX-2401 ONCOLYTIC ADENOVIRUS COMBINED WITH A SHORT COURSE OF DOSE-DENSE TEMOZOLOMIDE FOR RECURRENT GLIOBLASTOMA
Perez-Larraya, J. Gallego
Garcia-Moure, M.
Gonzalez-Huarriz, M.
Zalacain, M.
Marrodan, L.
Puigdelloses, M.
Labiano, S.
de la Nava, D.
Laspidea, V.
Ausejo, I.
Hervas, I.
Esparragosa, I.
Giraldez, M.
Dominguez, P.
Martinez-Simon, A.
Idoate, M.
Fueyo, J.
Gomez-Manzano, C.
Patino, A.
Diez-Valle, R.
Tejada, S.
Alonso, M.
NEURO-ONCOLOGY, 2023, 25 : 120 - 120
[23] Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma
Reardon, DA
Quinn, JA
Rich, JN
Desjardins, A
Vredenburgh, J
Gururangan, S
Sathornsumetee, S
Badruddoja, M
McLendon, R
Provenzale, J
Herndon, JE
Dowell, JM
Burkart, JL
Newton, HB
Friedman, AH
Friedman, HS
CANCER, 2005, 104 (07) : 1478 - 1486
[24] A phase II clinical trial evaluating the efficacy and safety of apatinib combined with dose-dense temozolomide in recurrent glioblastoma
Wang, Y.
Tao, R.
ANNALS OF ONCOLOGY, 2019, 30
[25] PHASE I TRIAL OF TEMOZOLOMIDE PLUS BEVACIZUMAB FOR NEWLY DIAGNOSED HIGH-GRADE GLIOMAS IN THE ELDERLY: INTERIM REPORT
Kono, M.
Arakawa, Y.
Mineharu, Y.
Ohka, F.
Kinoshita, M.
Nakae, S.
Miyashita, K.
Iuchi, T.
Hirose, Y.
Natsume, A.
Nakada, M.
Sasaki, H.
NEURO-ONCOLOGY, 2017, 19 : 81 - 81
[26] Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma
Bower, M
Newlands, ES
Bleehen, NM
Brada, M
Begent, RJH
Calvert, H
Colquhoun, I
Lewis, P
Brampton, MH
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1997, 40 (06) : 484 - 488
[27] Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma
M. Bower
E. S. Newlands
N. M. Bleehen
M. Brada
R. J. H. Begent
H. Calvert
I. Colquhoun
P. Lewis
M. H. Brampton
Cancer Chemotherapy and Pharmacology, 1997, 40 : 484 - 488
[28] PHASE I TRIAL OF HIGH DOSE TEMOZOLOMIDE (HDTMZ) WITH PERIPHERAL BLOOD STEM CELL SUPPORT (PBSCS) RESCUE IN RECURRENT HIGH-GRADE GLIOMA (HGG)
Frappaz, D.
Dussart, S.
Pierga, J.
Bay, J.
Fabbro, M.
Djafari, L.
Sunyach, M.
NEURO-ONCOLOGY, 2008, 10 (06) : 1068 - 1068
[29] OBJECTIVE RESPONSE AND CLINICAL BENEFIT IN RECURRENT EPENDYMOMA IN ADULTS: FINAL REPORT OF CERN 08-02: A PHASE II STUDY OF DOSE-DENSE TEMOZOLOMIDE AND LAPATINIB
Armstrong, Terri
Yuan, Ying
Wu, Jimin
Mendoza, Tito
Vera, Elizabeth
Omuro, Antonio
Lieberman, Frank
Robins, H.
Gerstner, Elizabeth
Wu, Jing
Wen, Patrick
Mikkelsen, Tom
Aldape, Kenneth
Gilbert, Mark
NEURO-ONCOLOGY, 2018, 20 : 241 - 241
[30] A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas
Karavasilis, Vasilios
Kotoula, Vassiliki
Pentheroudakis, George
Televantou, Despina
Lambaki, Sofia
Chrisafi, Sofia
Bobos, Mattheos
Fountzilas, George
JOURNAL OF NEUROLOGY, 2013, 260 (06) : 1469 - 1480

← 1 2 3 4 5 →